Pronunciation: [tˈɛɡɐfˌɜː] (IPA) 
The word "Tegafur" is a pharmaceutical name that is spelled phonetically as /tɛɡəfjʊr/. The first syllable "teg" is pronounced with a short "e" sound like "beg". The second syllable "a" is pronounced with a short "a" sound like "cat". The third syllable "fur" is pronounced with a short "u" sound like "hurt". The stress falls on the first syllable "teg". This medication is commonly used in the treatment of various types of cancer.
Tegafur is a pharmaceutical drug that belongs to the class of chemotherapeutic agents known as antimetabolites. It is an analog of fluorouracil (5-FU), which means it is structurally similar to fluorouracil. Tegafur is commonly used in combination with other drugs to treat various types of cancer, including stomach, colorectal, breast, and pancreatic cancers.
Tegafur functions as a prodrug, meaning it is metabolized within the body to its active component, 5-fluorouracil. Once converted, it works by inhibiting the synthesis of DNA and RNA, thereby interfering with the growth and replication of cancer cells. This mechanism of action helps to reduce tumor size and prevent further cancer cell proliferation.
Administered orally, tegafur is usually taken in the form of capsules or tablets. The exact dosage and treatment regimen depend on the specific type of cancer being treated, as well as individual patient factors. Tegafur may be used alone or in combination with other chemotherapeutic drugs or radiation therapy for improved efficacy.
As with any medication, tegafur can cause side effects, which may vary in severity. Common adverse effects include nausea, vomiting, loss of appetite, diarrhea, and fatigue. In some cases, more severe side effects such as myelosuppression, liver toxicity, or gastrointestinal ulcers may occur.
Overall, tegafur is an important component of cancer treatment regimens, often used in combination therapies, and its use should be closely monitored by healthcare professionals to ensure optimal efficacy and safety for patients.
